Dr. Brammer on Updates in the Treatment Landscape for T-Cell Lymphoma

Jonathan E. Brammer, MD
Published: Monday, Oct 30, 2017



Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses updates in the treatment landscape of T-cell lymphoma.

T-cell lymphoma has been an area of limited progress and poor prognosis, according to Brammer. An exciting development is with brentuximab vedotin (Adcetris), which is now being utilized for patients with relapsed CD30-positive anaplastic large-cell lymphoma. Some of those patients have long-term durable remissions.

For patients with cutaneous T-cell lymphoma, brentuximab vedotin is also highly effective, adds Brammer.
 


Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses updates in the treatment landscape of T-cell lymphoma.

T-cell lymphoma has been an area of limited progress and poor prognosis, according to Brammer. An exciting development is with brentuximab vedotin (Adcetris), which is now being utilized for patients with relapsed CD30-positive anaplastic large-cell lymphoma. Some of those patients have long-term durable remissions.

For patients with cutaneous T-cell lymphoma, brentuximab vedotin is also highly effective, adds Brammer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Rare Hematology: Advancing Care and Improving Outcomes for Patients with Aplastic AnemiaAug 31, 20181.0
Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in CareSep 29, 20181.5
Publication Bottom Border
Border Publication
x